Group items tagged

The pharmacy inquiry will explore issues impacting different types of pharmacy, with a particular focus on community, primary care and hospital pharmacy services. It will also consider current challenges around funding, workforce and the digital infrastructure. Planned developments within the profession will enable future pharmacists to be independent prescribers from day one of registration, giving them a greater role within primary care teams. Health and Social Care Committee Chair Steve Brine MP said: "It is clear that pharmacy has a central role to play in the future of the NHS. With a greater focus on personalised and patient-centred healthcare, we will be asking what more must be done to make sure that the profession is in the best shape to meet demand. "Better use of the pharmacy workforce would reduce pressures on general practice and hospitals. However, this will not happen without a planned workforce with the funding, supervision and training to support it. "At the end of the inquiry, the committee will be making recommendations to the government on what action needs to be taken to ensure the potential of pharmacy is realised.

At the Covid Inquiry on Tuesday, Sir Chris Wormald, permanent secretary at the Department of Health and Social Care (DHSC), was questioned about the initial exclusion of community pharmacies in the government's emergency pandemic life assurance scheme. Earlier this month, the National Pharmacy Association (NPA) submitted evidence to the inquiry highlighting the delay in including community pharmacies in the scheme - which offered £60,000 lump sum payments to NHS and care home staff who died from Covid. The inquiry heard that the scheme was launched on April 27, 2020, initially covering NHS and care home staff. However, then Health Secretary Matt Hancock only confirmed the inclusion of community pharmacy staff in a Tweet three days later, on April 30. NPA Chair Nick Kaye told the inquiry that it was "demoralising and demotivating" to community pharmacy staff who worked throughout the pandemic. Jacqueline Carey KC, Counsel to the Covid Inquiry, put the charge to Sir Wormald as he gave evidence about the department's response to the pandemic.

In its response to the Health and Social Care Committee inquiry into 'Digital Transformation in the NHS', the Community Pharmacy IT Group (CP ITG) has highlighted issues concerning the NHS community pharmacy. CP ITG, of which PSNC is a member, has urged that pharmacy teams should have access to up-to-date records information, e.g. from Shared Care Records, GP Connect and Summary Care Records with Additional Information. It has also stated that the Booking and Referral Standards (BaRS) should be extended so that future referrals into and from pharmacy can be communicated seamlessly. In its written response, CP ITG said: "Ensure that BaRS is expanded and aligns with other referral IT standards such as GP Connect referrals. Ensure it is used across community pharmacy, the GP sector, other health care sectors and across the NHS, and by all health IT suppliers, so that messages and referrals can flow smoothly within and across sectors and patients can have a seamless experience and safe care." The group has asked the Health and Social Care Committee to create a framework for the development of pharmacy IT to ensure IT suppliers are better equipped to support pharmacy teams and their delivery of services.

Nick Kaye, chair of the National Pharmacy Association (NPA), gave evidence to the UK's official COVID-19 Inquiry on Monday (4 November), highlighting the importance of building a "sustainable and resilient community pharmacy network" to enhance preparedness for future pandemics. Kaye also recommended utilising the existing community pharmacy infrastructure for public health initiatives, such as vaccination programmes, and stressed the need to recognise community pharmacists and their teams as integral members of primary care. "Seven pharmacies a week are closing across the four nations, and that is tragic for any future response. So, a resilient community pharmacy network that exists is going to be key," he told the Inquiry. He noted that 90 per cent of most NPA members' income comes from providing NHS services, underscoring the critical role pharmacies play in healthcare delivery. However, Kaye highlighted that pharmacies were often overlooked and underappreciated during the pandemic.

Community Pharmacy England (CPE) has cautioned that patients in the UK will continue to encounter difficulties in accessing medicines unless the government addresses supply problems and resolves the critical financial state of community pharmacies. CPE Chief Executive Janet Morrison and Mike Dent, Director of Pharmacy Funding, on Monday 19 February, gave evidence to the Health and Social Care Select Committee's Pharmacy Inquiry, highlighting the impact of ongoing medicines supply issues on pharmacies and patients. Morrison indicated that a combination of the ongoing "financial squeeze, operational pressures, and medicines supply and pricing issues" has left pharmacy businesses fighting for survival. "As the NHS continues to grapple with wider challenges, this is a battle that patients cannot afford for pharmacies to lose," she said. Morrison warned that if pharmacies continue to close, not only business owners and pharmacy teams will suffer, but patients and local communities will also face the consequences.

At the UK Covid-19 Inquiry's Module 3 hearings on 10 September, the National Pharmacy Association (NPA) highlighted that community pharmacy was "often overlooked and under-recognised" during the pandemic. Lawyer Lee John-Charles, speaking on behalf of the NPA, told the Inquiry that despite the central role played by community pharmacy in the delivery of NHS care throughout the pandemic, community pharmacists and their teams were "not given comparable treatment to other frontline healthcare workers." The NPA criticised the initial exclusion of pharmacy workers from the Life Assurance Scheme for frontline workers in England, calling on the Inquiry to investigate this notable omission. The NPA also pointed out that community pharmacies were forced to source and fund their own personal protective equipment (PPE) as it was not initially available to them through the NHS.

Chair of the Health and Social Care Committee Steve Brine MP has called on community pharmacy contractors to join a newly launched a parliamentary 'call for evidence' which will look into 'prevention' as a key to the future of the NHS. A former pharmacy minister and keen supporter of the sector, Mr Brine has called on all community pharmacists to "make their contribution count" by taking part in a major inquiry which will remain open for submission until Wednesday 8 February 2023 and will also involve general practitioners, nurses and other health professionals. Community pharmacists can submit their proposals written under 750 words, outlining what they think are the issues around prevention the parliamentary body should explore, why these issues deserve the Commons Select Committee's attention, and how government policy could be developed or improved to address them. The submissions will then be used to help the committee decide where it should focus its attention in the later stages of the inquiry on prevention, which is a vital part of the NHS Long Term Plan.

The Health and Social Care Select Committee (HSCC) on Tuesday held the first session in their pharmacy inquiry, with a panel of experts discussing the key issues facing community pharmacies in the country. Representatives from community pharmacy associations highlighted some of their biggest challenges and their vision for the future, as well as actions that government and NHS England can take to address those challenges for a better future for the sector. Opening the session, the Committee's vice-chair, Rachel Maskell MP, asked the representatives if they felt the government was ambitious enough in what it believes community pharmacy can do to address NHS pressures, or are pharmacists being held back by issues around workforce funding, contracting, and technological changes. Malcolm Harrison, Chief Executive, Company Chemists' Association (CCA), expressed that the government is not ambitious enough, saying "there's always opportunity to be more ambitious".

With the Pharmacy First services scheduled for launch end of this month, legislators explored the potential of community pharmacies to offer specific diagnostic and treatment services in the second public evidence session of pharmacy inquiry this week (January 16). The new service, which will enable pharmacists to offer advice and prescribe treatment for seven minor ailments, is expected to alleviate the pressure on the NHS, reduce GP workload, and cut waiting lists. But MPs and healthcare leaders also acknowledged that there's hesitancy and the mindset of 'GP first, not Pharmacy First' among members of the public. "We must accept that many patients are used to seeing their GP as their first port of call for many health conditions. Pharmacy First is welcome, but there are going to be some restrictions on how quickly some patients will want to take up some of those services, rather than seeing their GP," said William Pett, Head of Policy, Public Affairs and Research, Healthwatch England.

The government has responded to the Health and Social Care Select Committee's report on community pharmacy, acknowledging 17 of the 19 recommendations. In its report published on 29 May 2024, the Committee recommended, among other things, an overhaul of the Community Pharmacy Contractual Framework (CPCF), closing the funding gap, tackling medicines shortages by introducing generic substitution, and establishing an integrated and fully funded workforce plan for pharmacy. In its response, released today, the government stated that NHS England is currently conducting an economic analysis of the sector, which will inform future proposals for funding and contractual arrangements. On medicine shortages, it mentioned that the Department of Health and Social Care, working closely with NHS England, is taking forward a range of actions to improve their ability to mitigate and manage shortages and strengthen resilience. Additionally, the government has stated that it will "publish a refreshed Long Term Workforce Plan" this summer and is "committed to growing the pharmacy workforce."

Janet Morrison, CEO of Community Pharmacy England (CPE) has emphasised that stabilization of the sector is essential before any solutions can be delivered to fix the "struggling" health service. Speaking at the recent SIGMA UK Community Pharmacy Conference 2024, Janet described the current contract as "unaffordable" and warned that pharmacies are becoming "unsustainable." "Without an urgent funding uplift, the sector is facing a 'house of cards' collapse that will seriously impact communities, patients, and the safety of medicine supply. "So, first of all, we have to secure the stabilization. We have to make sure you can keep the lights on and the doors open, and that's critical," she stated. Janet pointed out that if the sector is stabilized and a fair deal is achieved, community pharmacies could effectively deliver solutions for the government that meet their policy goals. However, she noted that negotiations for the Community Pharmacy Contractual Framework (CPCF) for 2024-2025 cannot resume until the budget is published on October 30.

The Royal Pharmaceutical Society (RPS) presented key evidence to the UK COVID-19 Inquiry on 10 September, underscoring the vital role of pharmacists and pharmacy teams during the pandemic. Deirdre Domingo, legal representative for the RPS, delivered the statement during the Module 3 public hearings, which focus on the impact of COVID-19 on healthcare systems across the UK. As the professional body representing pharmacists and pharmaceutical scientists in Great Britain, the RPS urged the Inquiry to consider several critical issues: Recognition of pharmacists as key workers The RPS highlighted the crucial role pharmacy teams played in ensuring continued access to essential medicines and their integral involvement in the roll-out of COVID-19 and flu vaccinations. However, the Society also raised concerns over significant failures and challenges, such as inadequate safety measures to protect pharmacists at work, confusing national guidance, increased hostility towards healthcare professionals, and a disparity in the treatment of community pharmacy compared to NHS staff.

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

Pharmaceutical Services Negotiating Committee has submitted its evidence to the House of Commons Health and Social Care Select Committee's recent inquiry into 'The future of General Practice'. The committee, chaired by former health secretary Jeremey Hunt MP, had launched an inquiry to explore the future of NHS GP over the next five years. PSNC's evidence focused on what community pharmacy is currently doing to support GPs, and what more can be done in the future. The negotiator said: "We focused on how pharmacies supported patients throughout the pandemic as the only primary care access point offering healthcare advice on a walk-in basis.

The final report of the Infected Blood Inquiry has been published today, bringing to light a devastating chapter in the history of the UK's healthcare system. The inquiry, which was launched by former Prime Minister Theresa May in 2017, examined how contaminated blood products infected over 30,000 NHS patients with deadly viruses, including HIV and Hepatitis C, between the 1970s and 1990s. Following the publication of the report, Prime Minister Rishi Sunak issued a formal apology on behalf of successive governments, acknowledging the state's significant failings. He stated that he finds it "impossible to comprehend" how victims felt when injected with deadly diseases through no fault of their own.

Thousands of people in Britain infected with HIV and hepatitis C through contaminated blood transfusions will receive a compensation payment decades after the scandal, the government announced on Wednesday (August 17). The payment of £100,000 ($121,000) to each victim is an interim one after Brian Langstaff, the chairman of a public inquiry into the long-running scandal, last month recommended making immediate payouts before waiting for an ongoing inquiry to conclude. The former High Court judge said that the "moral case for compensation is beyond doubt". The government said the tax-free payments, to survivors of the scandal and bereaved partners of the thousands estimated to have died from the contaminated blood, would be made by the end of October. Thousands of people with haemophilia contracted hepatitis C and HIV after receiving blood transfusions, mainly from the United States, through the NHS in the 1970s, 1980s and 1990s. Due to a shortage of blood products in Britain, the NHS bought much of its stock from US suppliers whose donors, including prisoners and other groups at high risk of infection, had been paid for their blood.